中国医学创新2024，Vol.21Issue(15)：59-62,4.DOI:10.3969/j.issn.1674-4985.2024.15.014
盐酸哌罗匹隆联合丁螺环酮治疗难治性精神分裂症的临床研究
Clinical Study of Perospirone Hydrochloride Combined with Buspirone in the Treatment of Refractory Schizophrenia
摘要
Abstract
Objective:To investigate the clinical effect of Perospirone Hydrochloride combined with Buspirone in the treatment of refractory schizophrenia.Method:A total of 82 patients with refractory schizophrenia admitted to Fuzhou Third Hospital from June 2021 to December 2022 were divided into two groups according to random number table method.The control group(n=41)was treated with Risperidone combined with Buspirone,and the observation group(n=41)was treated with Perospirone Hydrochloride combined with Buspirone.The total effective rate,total incidence of adverse reactions and positive and negative syndrome scale(PANSS)scores and strategic decision support system(SDSS)scores before and after treatment were compared between the two groups.Result:The total effective rate of treatment in observation group was significantly higher than that in control group,and the total incidence of adverse reactions was significantly lower than that in control group(P<0.05).There were no significant differences in PANSS scores and SDSS scores between the two groups before treatment(P>0.05).After 6 and 12 weeks of treatment,PANSS scores and SDSS scores in observation group were significantly lower than those in control group(P<0.05).Conclusion:Perospirone Hydrochloride combined with Buspirone in the treatment of refractory schizophrenia has good clinical effect and high safety,which can significantly improve the social function of patients.关键词
盐酸哌罗匹隆/丁螺环酮/难治性精神分裂症/社会功能Key words
Perospirone Hydrochloride/Buspirone/Refractory schizophrenia/Social function引用本文复制引用
刘世坚..盐酸哌罗匹隆联合丁螺环酮治疗难治性精神分裂症的临床研究[J].中国医学创新,2024,21(15):59-62,4.基金项目
抚州市指导性科技计划项目(抚科社字[2022]9号序号71) （抚科社字[2022]9号序号71）
